RETATRUTIDE 10mg

Retarutide is an active compound named Retarutide released by Lilly in June 2023. It is a developed drug for the treatment of obesity and type 2 diabetes, based on Tirzepatide, a GLP/GI dual receptor agonist, and achieves triple (GLP-1/GIP/Gcg) agonist effect by hybridizing glucagon related structures. This active compound can activate receptor agonists in our body, helping to control blood sugar and manage weight loss.

Retaturtide works in a similar fashion to other weight loss drugs such as Saxenda, Mounjaro and Wegovy. But, it is also a GIP and glucagon receptor agonist. The medication is administered via injection only once a week.

Side Effects

The most common side effects of retatrutide are gastrointestinal, including nausea, diarrhea, vomiting, and constipation. These side effects were generally mild to moderate and occurred when the dose was increased. Heart rate increases were also reported in clinical trials, particularly with higher doses of retatrutide.

Interactions

As of now, specific drug interactions with retatrutide have not been reported in the search results. However, as with any medication, it's important to consult with a healthcare provider before combining retatrutide with other medications.

Dosing Guidelines

In clinical trials, retatrutide was dosed subcutaneously at four doses: 1 mg, 4 mg, 8 mg, and 12 mg. The specific dosing regimen and escalation were determined as part of the study design. However, as retatrutide is still under investigation, there are no established dosing guidelines for general use. Any use of retatrutide should be under the supervision of a healthcare provider and within the context of a clinical trial.